Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
about
Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/DoxAnti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signalingWNT5A-ROR2 is induced by inflammatory mediators and is involved in the migration of human ovarian cancer cell line SKOV-3Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease.Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Gα₁₂ drives invasion of oral squamous cell carcinoma through up-regulation of proinflammatory cytokinesAn IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor responseIntertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice.Ovarian epithelial-stromal interactions: role of interleukins 1 and 6.Gene expression profiling associated with angiotensin II type 2 receptor-induced apoptosis in human prostate cancer cellsAssessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions.Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer.Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma.Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells.Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targetsAre Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.Association among Dietary Flavonoids, Flavonoid Subclasses and Ovarian Cancer Risk: A Meta-Analysis.Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.Sprouty2 protein in prediction of post-treatment ascites in epithelial ovarian cancer treated with adjuvant carbotaxol chemotherapy.Crosstalk between Bcl-2 family and Ras family small GTPases: potential cell fate regulation?The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian CancerUtility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian massesIL‑6 and IL‑8 enhance factor H binding to the cell membranes.TLR agonists: our best frenemy in cancer immunotherapyIncreased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinomaTubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapyGetting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance.Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivationNF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma.Therapeutic targets and new directions for antibodies developed for ovarian cancer.
P2860
Q27853038-407676E5-7C53-46E6-B50A-B87539058B93Q27853281-301F1C68-4524-4BF8-989B-6776948E568FQ28477021-ECDCCD55-0128-49B0-ABD2-FA3DA6AA8EADQ28483751-AD92A45B-BD93-47A4-96D6-0D72A593618DQ33634911-9EEB0190-1D03-4B70-83DC-CD55BCD9B26AQ34178740-A0AA964B-2BFB-48B8-9542-04315107D01FQ34285363-22FDD68A-13CB-433F-8AAB-709B9E1CCF10Q34674172-79F40E62-0D4D-4B1D-9B80-E62F85BA32C7Q34704781-C058E80D-FB4D-4651-9975-DE013B99491CQ34770537-B8092574-E884-48DA-8D4B-6DD2C00FACD9Q34868121-231D4F15-21C0-42C8-88CB-D2BBA14E15BFQ34962993-287FAF5B-03E2-4A12-9CC3-51331EC5291BQ35101318-18115254-5CF3-4D14-85A6-E753B3145822Q35127888-DDBB8675-3842-4C07-B8D5-08AA55BEE518Q35142408-FB7E0BBE-D771-4587-964F-5DF52A44C2DFQ35157858-135AE721-8271-4282-99A0-41087A3AC012Q35342995-69750943-8691-4162-B4FE-12B5D9EA52BAQ35550177-56983F22-8AD2-444B-AB01-C31CC05FD459Q35684285-32AC9265-70E6-4361-B39A-378CE1A8E380Q35837949-D2B34776-31DF-48E1-B1C3-4324EC5B332FQ35853333-5F4F3ADE-4E0C-44A8-A6E6-68E05B0A98C0Q35907074-04C4DD2A-16AC-496E-BBBC-D413E1309E4FQ35917703-77CED8DE-453F-4988-B7C9-639AF21C0E28Q35951390-4D1BEB65-6D55-4929-86E5-D0BED4C2101CQ35964621-529C8F17-A1D3-46AB-940B-8CB2F3DBE0EAQ36057153-1113371B-2F34-4402-918F-33DE832D1986Q36516796-9977329E-1BFD-4213-9EC3-B4DF7D489E0FQ36563905-A21267F5-3F8E-4238-8482-58F175288E57Q36692881-D54B3CFC-6CBC-4EAB-BA47-87AE7BEE4811Q36817388-52939B60-D046-45CC-801D-72E48387D822Q36850457-55C891DA-80B5-44E5-BBF9-D7D37211BBA3Q36908883-1A34F46B-554F-4187-AEE1-7B9990055F48Q36980135-0A109CB2-2653-4BC0-8D59-CC16A9D68492Q37035522-11D48078-3BC8-4F4A-8E50-8F33BDA0E9A9Q37196532-53BA05CB-C8E0-45C0-A616-330A4289D516Q37249509-6C253A38-08DC-4CC3-9347-9081ADB6C92AQ37299698-BF860364-2E9E-4A40-B69F-9F2AE79CD555Q37309839-20DC0B43-1170-4F84-877D-E2C2659710E7Q37392765-BBB62215-2E1C-4044-AD70-E93F8317605DQ37397674-BE0D94A7-AA6A-436B-8C81-8A5072C5748F
P2860
Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Autocrine production of interl ...... tance in ovarian cancer cells.
@en
Autocrine production of interl ...... tance in ovarian cancer cells.
@nl
type
label
Autocrine production of interl ...... tance in ovarian cancer cells.
@en
Autocrine production of interl ...... tance in ovarian cancer cells.
@nl
prefLabel
Autocrine production of interl ...... tance in ovarian cancer cells.
@en
Autocrine production of interl ...... tance in ovarian cancer cells.
@nl
P2093
P1433
P1476
Autocrine production of interl ...... tance in ovarian cancer cells.
@en
P2093
Ling Zhi Li
Wei Jia Sun
Xiu Long Niu
Ya Qin Zhu
P304
P356
10.1016/J.CANLET.2010.02.019
P407
P577
2010-03-16T00:00:00Z